Brittany Knick Ragon1, Olatoyosi Odenike2, Maria R Baer3, Wendy Stock2, Gautam Borthakur4, Keyur Patel4, Lina Han4, Helen Chen5, Helen Ma4, Loren Joseph6, Yang Zhao7, Keith Baggerly7, Marina Konopleva4, Nitin Jain8. 1. Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Atrium Health, Charlotte, NC. 2. Department of Medicine, University of Chicago Medical Center, Chicago, IL. 3. University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, MD. 4. Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX. 5. Cancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD. 6. Division of Clinical Pathology, Beth Israel Deaconess Medical Center, Boston, MA. 7. Department of Bioinformatics and Computational Biology, University of Texas MD Anderson Cancer Center, Houston, TX. 8. Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX. Electronic address: njain@mdanderson.org.
Abstract
BACKGROUND: With proven single-agent activity and favorable toxicity profile of MEK-1/2 inhibition in advanced leukemia, investigation into combination strategies to overcome proposed resistance pathways is warranted. Resistance to MEK inhibition is secondary to upstream hyperactivation of RAS/RAF or activation of the PI3K/PTEN/AKT/mTOR pathway. This phase II multi-institution Cancer Therapy Evaluation Program-sponsored study was conducted to determine efficacy and safety of the combination of the ATP-competitive pan-AKT inhibitor GSK2141795, targeting the PI3K/AKT pathway, and the MEK inhibitor trametinib in RAS-mutated relapsed/refractory acute myeloid leukemia (AML). PATIENTS AND METHODS: The primary objective was to determine the proportion of patients achieving a complete remission. Secondary objectives included assessment of toxicity profile and biologic effects of this combination. Twenty-three patients with RAS-mutated AML received the combination. Two dose levels were explored (dose level 1: 2 mg trametinib, 25 mg GSK2141795 and dose level 2: 1.5 mg trametinib, 50 mg GSK2141795). RESULTS: Dose level 1 was identified as the recommended phase II dose. No complete remissions were identified in either cohort. Minor responses were recognized in 5 (22%) patients. The most common drug-related toxicities included rash and diarrhea, with dose-limiting toxicities of mucositis and colitis. Longitudinal correlative assessment of the modulation of MEK and AKT pathways using reverse phase protein array and phospho-flow analysis revealed significant and near significant down-modulation of pERK and pS6, respectively. Combined MEK and AKT inhibition had no clinical activity in patients with RAS-mutated AML. CONCLUSION: Further investigation is required to explore the discrepancy between the activity of this combination on leukemia cells and the lack of clinical efficacy.
BACKGROUND: With proven single-agent activity and favorable toxicity profile of MEK-1/2 inhibition in advanced leukemia, investigation into combination strategies to overcome proposed resistance pathways is warranted. Resistance to MEK inhibition is secondary to upstream hyperactivation of RAS/RAF or activation of the PI3K/PTEN/AKT/mTOR pathway. This phase II multi-institution Cancer Therapy Evaluation Program-sponsored study was conducted to determine efficacy and safety of the combination of the ATP-competitive pan-AKT inhibitor GSK2141795, targeting the PI3K/AKT pathway, and the MEK inhibitor trametinib in RAS-mutated relapsed/refractory acute myeloid leukemia (AML). PATIENTS AND METHODS: The primary objective was to determine the proportion of patients achieving a complete remission. Secondary objectives included assessment of toxicity profile and biologic effects of this combination. Twenty-three patients with RAS-mutated AML received the combination. Two dose levels were explored (dose level 1: 2 mg trametinib, 25 mg GSK2141795 and dose level 2: 1.5 mg trametinib, 50 mg GSK2141795). RESULTS: Dose level 1 was identified as the recommended phase II dose. No complete remissions were identified in either cohort. Minor responses were recognized in 5 (22%) patients. The most common drug-related toxicities included rash and diarrhea, with dose-limiting toxicities of mucositis and colitis. Longitudinal correlative assessment of the modulation of MEK and AKT pathways using reverse phase protein array and phospho-flow analysis revealed significant and near significant down-modulation of pERK and pS6, respectively. Combined MEK and AKT inhibition had no clinical activity in patients with RAS-mutated AML. CONCLUSION: Further investigation is required to explore the discrepancy between the activity of this combination on leukemia cells and the lack of clinical efficacy.
Authors: M R Ricciardi; T McQueen; D Chism; M Milella; E Estey; E Kaldjian; J Sebolt-Leopold; M Konopleva; M Andreeff Journal: Leukemia Date: 2005-09 Impact factor: 11.528
Authors: M Milella; S M Kornblau; Z Estrov; B Z Carter; H Lapillonne; D Harris; M Konopleva; S Zhao; E Estey; M Andreeff Journal: J Clin Invest Date: 2001-09 Impact factor: 14.808
Authors: Christian H Brandts; Bülent Sargin; Miriam Rode; Christoph Biermann; Beate Lindtner; Joachim Schwäble; Horst Buerger; Carsten Müller-Tidow; Chunaram Choudhary; Martin McMahon; Wolfgang E Berdel; Hubert Serve Journal: Cancer Res Date: 2005-11-01 Impact factor: 12.701
Authors: S Zhao; M Konopleva; M Cabreira-Hansen; Z Xie; W Hu; M Milella; Z Estrov; G B Mills; M Andreeff Journal: Leukemia Date: 2004-02 Impact factor: 11.528
Authors: Jens T Siveke; Smiths S Lueong; Ben Zhao; Laura Dierichs; Jiang-Ning Gu; Marija Trajkovic-Arsic; Ralf Axel Hilger; Konstantinos Savvatakis; Silvia Vega-Rubin-de-Celis; Sven-Thorsten Liffers; Samuel Peña-Llopis; Diana Behrens; Stephan Hahn Journal: Cell Death Discov Date: 2020-03-11
Authors: Ashwini S Kamath-Loeb; Jiang-Cheng Shen; Michael W Schmitt; Brendan F Kohrn; Keith R Loeb; Elihu H Estey; Jin Dai; Sylvia Chien; Lawrence A Loeb; Pamela S Becker Journal: Leuk Res Date: 2022-03-09 Impact factor: 3.715
Authors: William G Herrick; Casey L Kilpatrick; Melinda G Hollingshead; Dominic Esposito; Geraldine O'Sullivan Coyne; Andrea M Gross; Barry C Johnson; Alice P Chen; Brigitte C Widemann; James H Doroshow; Ralph E Parchment; Apurva K Srivastava Journal: Mol Cancer Ther Date: 2021-02-03 Impact factor: 6.009
Authors: Jens T Siveke; Smiths S Lueong; Ben Zhao; Laura Dierichs; Jiang-Ning Gu; Marija Trajkovic-Arsic; Ralf Axel Hilger; Konstantinos Savvatakis; Silvia Vega-Rubin-de-Celis; Sven-Thorsten Liffers; Samuel Peña-Llopis; Diana Behrens; Stephan Hahn Journal: Cell Death Discov Date: 2020-03-11